SCHEMBL22443617

SCHEMBL22443617

CC1(C)CCC[C@H](C=O)N1Cc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ ELANE P08246 1/20 0.39
▸ ACHE P22303 1/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ DRD2 P14416 2/20 0.37
▸ DRD4 P21917 2/20 0.37
▸ DRD3 P35462 2/20 0.37
▸ HSD11B1 P28845 1/20 0.37
▸ AMPD2 Q01433 1/20 0.37
▸ PREP P48147 1/20 0.37
▸ CXCR3 P49682 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.36
▸ ACE P12821 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22443618 1.00 ALDH1A1 (0.40) ALDH1A1GAAELANEACHEKMT2A
SCHEMBL22443728 1.00 ALDH1A1 (0.40) ALDH1A1GAAELANEACHEKMT2A
SCHEMBL22443666 0.91 GAA (0.41) ALDH1A1GAAELANEACHELMNA
SCHEMBL22443677 0.91 GAA (0.41) ALDH1A1GAAELANEACHELMNA
SCHEMBL22443667 0.91 GAA (0.41) ALDH1A1GAAELANEACHELMNA
SCHEMBL22453840 0.77 VEGFA (0.43) ACHESIGMAR1
SCHEMBL22443386 0.76 SPHK2 (0.41) ALDH1A1ACHESIGMAR1
Ammonia Solution, Strong SCHEMBL29243782 0.76 CCR3 (0.41) —
SCHEMBL22443385 0.76 SPHK2 (0.41) ALDH1A1ACHESIGMAR1
SCHEMBL22443391 0.73 ALDH1A1 (0.40) ALDH1A1ACHEKMT2AMEN1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220152004-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2022-05-19 — — US disclosed
US-20220152004-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2022-05-19 — — US disclosed
EP-3941468-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA Atrogi AB (SE) 2022-01-26 — — EP disclosed
CN-113784953-A Heterocyclyl (phenyl) carbinol compounds useful for treating hyperglycemia 阿托基公司 2021-12-10 — — CN disclosed
WO-2020188301-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2020-09-24 — — WO disclosed
WO-2020188301-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2020-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220152004-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA GPR119, SLC5A1, SLC5A2 ALDH1A1 653/4885GAA 250/4885ELANE 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback